May 10, 2023

NRx Pharmaceuticals Reschedules First Quarter 2023 Financial Results Conference Call

RADNOR, Pa., May 10, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it is rescheduling its first quarter quarterly investor conference call previously scheduled for Thursday, May 11, 2023 at 4:30pm ET to Tuesday, May 16, 2023 at 8:30am ET, due to scheduling conflicts. The Company's first quarter 2023 earnings press release is expected to be issued on the morning of May 16, 2023, followed by an investor conference call hosted by management at 8:30am ET that day.

A live webcast of the conference call will be available on the Company's website at https://ir.nrxpharma.com/news-events/ir-calendar. An archive of the webcast will be available on the Company's website for 30 days.

Participants that are unable to join the webcast can access the conference call via telephone by dialing domestically +1 (833) 630-1956 or internationally +1 (412) 317-1837.

About NRx Pharmaceuticals

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics for the treatment of central nervous system disorders, specifically bipolar depression with suicidality and post-traumatic stress disorder (PTSD). The company's lead program NRX-101, an oral, fixed-dose combination of D-cycloserine and lurasidone, targets the brain's N-methyl-D-aspartate (NMDA) receptor and is being investigated in a Phase 2b/3 clinical trial for suicidal treatment-resistant bipolar depression, which includes patients with both acute and sub-acute suicidality, an indication for which the only approved treatment is electroshock therapy. The company's prior Phase 2 STABIL-B clinical trial evaluating NRX-101 in patients with Severe Bipolar Depression with Acute Suicidal Ideation & Behavior (ASIB) demonstrated a substantial improvement over available therapy in reducing depression and suicidality compared to placebo when patients were treated with NRX-101 after a single dose of ketamine. Based on the findings from the STABIL-B trial, the U.S. Food and Drug Administration (FDA) granted a Special Protocol Agreement and Breakthrough Therapy Designation for NRX-101 in patients with Severe Bipolar Depression with ASIB.

SOURCE NRx Pharmaceuticals, Inc.

For further information: CORPORATE, Matthew Duffy, Chief Business Officer, mduffy@nrxpharma.com; INVESTOR RELATIONS, Suzanne Messere, Investor Relations, suzanne.messere@sternir.com

---